Physician profile
Camille A Kantai
NPI 1720361314
$3,654.15
in general payments reported to CMS, 2019-2025
28 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 93% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $505 · 2023: $727 · 2024: $862 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Consulting Fee: $900 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.42 |
| Consulting Fee | $900.00 |
| Education | $298.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $815.37 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $626.19 | 2022-2025 | |
| Grifols USA, LLC | $372.06 | 2021-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $191.02 | 2021-2023 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $186.50 | 2021-2025 | Dupixent |
| Avadel Cns Pharmaceuticals, LLC | $172.75 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $168.17 | 2021-2025 | |
| United Therapeutics Corporation | $153.74 | 2021-2023 | Tyvaso |
| Amgen INC. | $128.48 | 2022-2025 | Tezspire |
| Harmony Biosciences LLC | $123.36 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $122.65 | 2021-2024 | |
| Insmed, INC. | $79.23 | 2024-2025 | Arikayce, Brinsupri |
| Optinose US, INC. | $62.93 | 2021-2022 | |
| Verona Pharma, INC. | $52.26 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $48.73 | 2022-2023 | Yupelri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.46 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $46.78 | 2021 | |
| Viatris Specialty LLC | $42.91 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $41.07 | 2024-2025 | Inspire |
| Philips North America LLC | $35.58 | 2022 | |
| Resmed Corp | $27.28 | 2025 | |
| Pulmonx Corporation | $22.69 | 2022 | |
| Abbvie INC. | $17.29 | 2023 | |
| Liquidia Technologies, INC. | $15.97 | 2025 | Yutrepia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.87 | 2021 | |
| Axsome Therapeutics, INC. | $13.52 | 2023 | Sunosi |
| Apria Healthcare LLC | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Kantai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.